NasdaqGS:BCRXBiotechs
Can BioCryst Pharmaceuticals (BCRX) Be Worth More As A New CSO Sharpens Its Pipeline Story?
BioCryst Pharmaceuticals (BCRX) has created a new Chief Scientific Officer role and appointed David W. Jenkins, an industry veteran with broad R&D and external innovation experience, a move investors may watch closely.
See our latest analysis for BioCryst Pharmaceuticals.
The appointment of a new Chief Scientific Officer comes as BioCryst Pharmaceuticals trades at US$9.29, with a 1-day share price return of 2.03% but a 7-day share price return down 6.26%. Its year-to-date share price return...